{"id":"W3083498943","doi":"10.1158/1538-7445.am2020-ct150","title":"Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Rash; Cancer; Renal cell carcinoma; Lung cancer; Melanoma; Oncology; Gastroenterology; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007484726,0.00165901,0.001507857,0.0003609923,0.0003932115,0.0008308894,0.0008023744,0.001062497,0.005700727],"category_scores_gemma":[0.000468757,0.0005091131,0.000898634,0.0003929516,0.0006866578,0.0007108854,0.0003523738,0.00254254,0.00144403],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052664,"about_ca_system_score_gemma":0.001484532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001306385,"about_ca_topic_score_gemma":0.003137283,"domain_scores_codex":[0.9997597,0.00008554292,0.00001478239,0.00005051511,0.00002760579,0.00006174284],"domain_scores_gemma":[0.9996946,0.00003042871,0.00004958564,0.00002589373,0.00001863715,0.0001809919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5748054,0.09563764,0.009622741,0.001278451,0.001323401,0.000682524,0.0004349595,0.003359038,0.184706,0.0005389766,0.009692748,0.1179182],"study_design_scores_gemma":[0.3902838,0.5776803,0.01453764,0.00004095631,0.0004651365,0.0005487232,0.00006039275,0.0009436831,0.01054686,0.000150518,0.00471216,0.00002979809],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874764,0.001371155,0.0007248917,0.000325431,0.00007538597,0.004521439,0.002806842,0.0001677728,0.002530785],"genre_scores_gemma":[0.9832233,0.001339904,0.001687439,0.0007556322,0.0001115615,0.003702902,0.004724672,0.00004427196,0.004410463],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005700727,"threshold_uncertainty_score":0.01907086,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0506028019822661,"score_gpt":0.3909846976816892,"score_spread":0.3403818956994231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}